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Data from the ongoing inﬂuenza A(H1N1) pandemic have
shown that early antiviral treatment is crucial to reduce morbidity
and mortality.1 The numbers likely to receive oseltamivir over
future inﬂuenza seasons make it imperative to be aware of any
oseltamivir-related severe adverse effects, given that the winter is
by now long over. We report two patients with suspected
oseltamivir-induced bradycardia.
A 39-year-old woman was admitted at 19 weeks of pregnancy
for amnionitis conﬁrmed by amniocentesis. Antibiotic treatment
was initiated and termination of the pregnancy performed. The
following evening, due to cough and suspected inﬁltrate on chest
radiography, oseltamivir (75 mg twice daily)was started. Two days
later, sinus bradycardia appeared, decreasing gradually to 40–45
bpm at rest (Figure 1). She was asymptomatic, with no additional
dysrhythmias on electrocardiography and Holter monitoring two
days later. Oseltamivir was discontinued for suspected oseltami-
vir-induced bradycardia; H1N1 PCR was subsequently negative.
An overweight 24-year-old woman, hypertensive and on
ﬂuoxetine for an eating disorder, was hospitalized with a
presumptive diagnosis of H1N1 inﬂuenza, subsequently validated
by PCR. Oseltamivir 75 mg twice daily was initiated, with
roxithromycin and bronchodilator inhalations. The next day, the
oseltamivir dose was doubled due to increasing dyspnea, then
reduced one day later to the standard dose. The admission heart[(Figure_1)TD$FIG]
Figure 1. Temperature and pul
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subsequently experienced repeated episodes of bradycardia,
occasionally accompanied by dizziness or pre-syncope. Holter
testing showed an average rate of 51 bpm, with multiple
bradycardic episodes. Respiratory symptoms and fever had by
then resolved; oseltamivir and ﬂuoxetine were discontinued.
Of the patients’ medications other than oseltamivir, none is
known to be associatedwith bradycardia. Thyroid function, cardiac
enzymes, and echocardiography were normal, and neither woman
experienced hypoxia. While the Naranjo score2 for both cases was
3 (possible adverse drug reaction), the appearance of bradycardia
in conjunction with resolution of the admission diagnosis
(amnionitis/inﬂuenza) in both women supports a drug reaction.
Repeat cardiac Holter testing several weeks later was normal.
While both mild and severe adverse effects have been reported
for oseltamivir,3,4 we could ﬁnd no published reports of
oseltamivir-induced bradycardia. Roche prescribing information
mentions cardiac arrhythmias in the post-marketing assessment,
but gives no further information.5 We consider it probable that
oseltamivir can cause bradycardia, an adverse event with
potentially severe consequences; however, the lack of previous
reports would indicate that it is relatively rare. Awareness of the
possibility of oseltamivir-induced bradycardia will improve
diagnosis if such an adverse effect exists; further post-marketing
studies focusing on cardiac dysrhythmias are needed to validate
the possibility.se rate chart for patient 1.
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